NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption

European Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2011, Pages 121-127

  Kim, Sang Heon ^a   Kim, Sang Hoon ^b   Yoon, Ho Joo ^a   Shin, Dong Ho ^a   Park, Sung Soo ^a   Kim, Youn Seup ^c   Park, Jae Seuk ^c   Jee, Young Koo ^c  

^a Hanyang University College of Medicine   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c Dankook University College of Medicine   (South Korea)

Author keywords

Anti TB drugs; Drug metabolizing enzymes; Maculopapular eruption; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG TUBERCULOSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOUS PLEURISY;

ADULT; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2E1; DRUG ERUPTIONS; EXANTHEMA; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79151483041     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0912-4     Document Type: Article

References (31)

1. HM Blumberg WJ Burman RE Chaisson CL Daley SC Etkind LN Friedman P Fujiwara M Grzemska PC Hopewell MD Iseman RM Jasmer V Koppaka RI Menzies RJ O'Brien RR Reves LB Reichman PM Simone JR Starke AA Vernon 2003 American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 167 4 603 662 10.1164/rccm.167.4.603 12588714
2. EJ Forget D Menzies 2006 Adverse reactions to first-line antituberculosis drugs Expert Opin Drug Saf 5 2 231 249 1:CAS:528:DC%2BD28XhvVKnsbo%3D 10.1517/14740338.5.2.231 16503745
3. D Yee C Valiquette M Pelletier I Parisien I Rocher D Menzies 2003 Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 11 1472 1477 10.1164/rccm.200206-626OC 12569078
4. WC Tan CK Ong SC Kang MA Razak 2007 Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs Med J Malaysia 62 2 143 146 1:STN:280:DC%2BD1crit12rug%3D%3D 18705448
5. T Schaberg K Rebhan H Lode 1996 Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis Eur Respir J 9 10 2026 2030 1:CAS:528:DyaK28XmvF2iu7Y%3D 10.1183/09031936.96.09102026 8902462
6. A Tostmann MJ Boeree RE Aarnoutse WC de Lange AJ van der Ven R Dekhuijzen 2008 Antituberculosis drug-induced hepatotoxicity: concise up-to-date review J Gastroenterol Hepatol 23 2 192 202 1:CAS:528:DC%2BD1cXkslKgt7g%3D 10.1111/j.1440-1746.2007.05207.x 17995946
7. S Roychowdhury CK Svensson 2005 Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin AAPS J 7 4 E834 E846 1:CAS:528: DC%2BD28XhsVeitrw%3D 10.1208/aapsj070480 16594635
8. JL Walgren MD Mitchell DC Thompson 2005 Role of metabolism in drug-induced idiosyncratic hepatotoxicity Crit Rev Toxicol 35 4 325 361 1:CAS:528:DC%2BD2MXltlCqtLs%3D 10.1080/10408440590935620 15989140
9. AY Lee MJ Kim WY Chey J Choi BG Kim 2004 Genetic polymorphism of cytochrome P450 2 C9 in diphenylhydantoin-induced cutaneous adverse drug reactions Eur J Clin Pharmacol 60 3 155 159 1:CAS:528:DC%2BD2cXjvFKnt7o%3D 10.1007/s00228-004-0753-0 15024534
10. TC Sarich M Youssefi T Zhou SP Adams RA Wall JM Wright 1996 Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits Arch Toxicol 70 12 835 840 1:CAS:528:DyaK28XntVWgs7o%3D 10.1007/s002040050347 8911642
11. N Singh S Dubey S Chinnaraj A Golani A Maitra 2009 Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients Mol Diagn Ther 13 1 49 58 1:CAS:528:DC%2BD1MXmtV2isbc%3D 19351215
12. F Sun Y Chen Y Xiang S Zhan 2008 Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis Int J Tuberc Lung Dis 12 9 994 1002 1:STN:280: DC%2BD1crjsFShug%3D%3D 18713495
13. YS Huang HD Chern WJ Su JC Wu SL Lai SY Yang FY Chang SD Lee 2002 Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis Hepatology 35 4 883 889 1:CAS:528:DC%2BD38XjtFSksLw%3D 10.1053/jhep.2002.32102 11915035
14. SH Kim JW Bahn YK Kim YS Chang ES Shin YS Kim JS Park BH Kim IJ Jang J Song HS Park KU Min YK Jee 2009 Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis Pharmacogenomics 10 11 1767 1779 1:CAS:528:DC%2BD1MXhtlOiu77O 10.2217/pgs.09.100 19891553
15. LG Possuelo JA Castelan TC de Brito AW Ribeiro PI Cafrune PD Picon AR Santos RL Teixeira TS Gregianini MH Hutz ML Rossetti A Zaha 2008 Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil Eur J Clin Pharmacol 64 7 673 681 1:CAS:528:DC%2BD1cXmtlSjsro%3D 10.1007/s00228-008-0484-8 18421452
16. YS Huang HD Chern WJ Su JC Wu SC Chang CH Chiang FY Chang SD Lee 2003 Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis Hepatology 37 4 924 930 1:CAS:528:DC%2BD3sXjt1Wlurc%3D 10.1053/jhep.2003.50144 12668988
17. N Vuilleumier MF Rossier A Chiappe F Degoumois P Dayer B Mermillod L Nicod J Desmeules D Hochstrasser 2006 CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis Eur J Clin Pharmacol 62 6 423 429 1:CAS:528:DC%2BD28XnsVCgsLg%3D 10.1007/s00228-006-0111-5 16770646
18. B Roy A Chowdhury S Kundu A Santra B Dey M Chakraborty PP Majumder 2001 Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation J Gastroenterol Hepatol 16 9 1033 1037 1:CAS:528:DC%2BD3MXotlylurw%3D 10.1046/j.1440-1746.2001.02585.x 11595069
19. V Leiro A Fernandez-Villar D Valverde L Constenla R Vazquez L Pineiro A Gonzalez-Quintela 2008 Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population Liver Int 28 6 835 839 1:CAS:528:DC%2BD1cXovVCgsb4%3D 10.1111/j.1478-3231.2008.01700.x 18397238
20. SH Kim HJ Yoon DH Shin SS Park YS Kim JS Park YK Jee 2010 GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans Tuberculosis (Edinb) 90 1 39 43 1:CAS:528:DC%2BC3cXmt1KgsLg%3D 10.1016/j.tube.2009.12.001
21. KA Phillips DL Veenstra E Oren JK Lee W Sadee 2001 Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 18 2270 2279 1:CAS:528:DC%2BD3MXosFCktro%3D 10.1001/jama.286.18.2270 11710893
22. CH Lee JY Hwang DK Oh MK Kee E Oh JW An J Kim H Do HJ Kim SS Kim H Kim JG Nam 2010 The burden and characteristics of tuberculosis/human immunodeficiency virus (TB/HIV) in South Korea: a study from a population database and a survey BMC Infect Dis 10 66 10.1186/1471-2334-10-66 20226025
23. W Han D Kang IA Park SW Kim JY Bae KW Chung DY Noh 2004 Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features Clin Cancer Res 10 1 Pt 1 124 130 1:CAS:528:DC%2BD2cXkvF2nsg%3D%3D 10.1158/1078-0432.CCR-0834-3 14734460
24. J Kirchheiner J Brockmoller 2005 Clinical consequences of cytochrome P450 2 C9 polymorphisms Clin Pharmacol Ther 77 1 1 16 1:CAS:528:DC%2BD2MXks1Wh 10.1016/j.clpt.2004.08.009 15637526
25. JW Bae HK Kim JH Kim SI Yang MJ Kim CG Jang YS Park SY Lee 2005 Allele and genotype frequencies of CYP2C9 in a Korean population Br J Clin Pharmacol 60 4 418 422 1:CAS:528:DC%2BD2MXhtFylt73E 10.1111/j.1365-2125.2005.02448.x 16187974
26. J Blaisdell LF Jorge-Nebert S Coulter SS Ferguson SJ Lee B Chanas T Xi H Mohrenweiser B Ghanayem JA Goldstein 2004 Discovery of new potentially defective alleles of human CYP2C9 Pharmacogenetics 14 8 527 537 1:CAS:528: DC%2BD2cXmtVGgtbs%3D 10.1097/01.fpc.0000114759.08559.51 15284535
27. JA Goldstein T Ishizaki K Chiba SM de Morais D Bell PM Krahn DA Evans 1997 Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1 59 64 1:CAS:528:DyaK2sXislOkt74%3D 10.1097/00008571-199702000-00008 9110363
28. M Ohno I Yamaguchi I Yamamoto T Fukuda S Yokota R Maekura M Ito Y Yamamoto T Ogura K Maeda K Komuta T Igarashi J Azuma 2000 Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity Int J Tuberc Lung Dis 4 3 256 261 1:STN:280:DC%2BD3c3htlWhtw%3D%3D 10751073
29. WH Chung SI Hung YT Chen 2007 Human leukocyte antigens and drug hypersensitivity Curr Opin Allergy Clin Immunol 7 4 317 323 1:CAS:528: DC%2BD2sXpsVKlsbw%3D 10.1097/ACI.0b013e3282370c5f 17620823
30. WH Chung SI Hung HS Hong MS Hsih LC Yang HC Ho JY Wu YT Chen 2004 Medical genetics: a marker for Stevens-Johnson syndrome Nature 428 6982 486 1:CAS:528:DC%2BD2cXis1Gksro%3D 10.1038/428486a 15057820
31. SI Hung WH Chung SH Jee WC Chen YT Chang WR Lee SL Hu MT Wu GS Chen TW Wong PF Hsiao WH Chen HY Shih WH Fang CY Wei YH Lou YL Huang JJ Lin YT Chen 2006 Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions Pharmacogenet Genomics 16 4 297 306 1:CAS:528:DC%2BD28Xit12ht7g%3D 10.1097/01.fpc.0000199500.46842.4a 16538176